CJC-1295 (no DAC)
CJC-1295 without DAC, also known as Modified GRF (1-29) or Mod GRF 1-29, is a synthetic 29-amino-acid analog of growth-hormone-releasing hormone (GHRH). It is supplied as a reference standard for in-vitro GHRH-receptor binding and analytical characterization research.
View product · from $55What it is
CJC-1295 (no DAC) is a synthetic peptide corresponding to the first 29 residues of human growth-hormone-releasing hormone (GHRH 1-29), carrying four amino-acid substitutions relative to the native sequence that are introduced to increase its resistance to enzymatic and oxidative degradation during synthesis and storage. The canonical modifications are a D-alanine at position 2 (in place of L-Ala), together with substitutions at positions 8, 15, and 27 of the parent GRF (1-29) framework. "No DAC" distinguishes this molecule from the DAC-conjugated CJC-1295, which carries an additional N-epsilon-maleimidopropionyl-lysine extension at the C-terminus; the no-DAC form lacks that albumin-binding moiety and therefore has a distinct molecular weight and chromatographic profile. It is handled strictly as a research-grade reference peptide and analytical standard, not as a therapeutic article.
Mechanism (in-vitro research context)
In in-vitro systems, CJC-1295 (no DAC) is studied as a peptide ligand of the growth-hormone-releasing-hormone receptor (GHRHR), a class B (secretin-family) G-protein-coupled receptor. In receptor-expressing cell models, GHRH-family peptides engage GHRHR and are associated in the published literature with Gs-coupled adenylyl-cyclase activation and cyclic-AMP accumulation; CJC-1295 (no DAC) serves as a reference agonist analog for characterizing receptor binding affinity, occupancy, and downstream second-messenger readouts in these assay systems. The four substitutions relative to native GHRH (1-29) are of interest in structure-activity research examining peptide stability and receptor interaction. All such work is conducted in cell-free or cultured-cell systems for biochemical and pharmacological characterization only.
Research areas
- GHRH-receptor (GHRHR) binding and competitive-displacement assays in receptor-expressing cell lines
- Gs/adenylyl-cyclase and cyclic-AMP second-messenger signaling readouts in vitro
- Peptide structure-activity relationship studies comparing native GHRH (1-29) with substituted analogs
- Enzymatic and oxidative stability profiling of modified GHRH analogs in solution
- Analytical method development and reference-standard characterization by RP-HPLC and mass spectrometry
Chemistry
- Molecular weight
- 3367.93 g/mol
- CAS
- 863288-34-0
- Formula
- C152H252N44O42
- Sequence
- Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 (C-terminal amide; one-letter, with D-Ala at position 2): Y-[D-Ala]-DAIFTQSYRKVLAQLSARKLLQDILSR-NH2
Laboratory handling
Supplied as a lyophilized powder. For long-term storage, keep the lyophilized solid at -20 °C, protected from light and moisture. Once reconstituted in an appropriate analytical solvent, store at 2–8 °C for short-term use and prepare frozen aliquots at -20 °C to minimize freeze-thaw cycles; confirm identity and stability analytically (e.g., RP-HPLC, mass spectrometry) before use. As a peptide containing oxidation- and degradation-prone residues, repeated freeze-thaw and prolonged solution storage may reduce measured purity, so stability should be verified rather than assumed.
FAQ
What is the amino acid sequence?
It is a 29-residue GHRH (1-29) analog with a C-terminal amide: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2, with a D-alanine at position 2 and substitutions at positions 8, 15, and 27 relative to native GHRH (1-29).
How does CJC-1295 (no DAC) differ from CJC-1295 with DAC?
The no-DAC form is Modified GRF (1-29) without the C-terminal N-epsilon-maleimidopropionyl-lysine (DAC) extension present in the DAC-conjugated version. The two therefore differ in molecular weight, molecular formula, and chromatographic retention, which is relevant when selecting a reference standard.
What is the molecular weight and formula?
The reported molecular weight is approximately 3367.93 g/mol, with molecular formula C152H252N44O42 for the free-base (C-terminal amide) peptide (net acetate or trifluoroacetate counter-ion content depends on the supplied salt form).
How is purity verified?
Identity and purity are typically assessed by reversed-phase HPLC for chromatographic purity and by mass spectrometry (e.g., ESI- or MALDI-MS) to confirm the expected monoisotopic/average mass; amino-acid analysis or sequencing may be used for additional confirmation.
How should it be stored in the laboratory?
Store the lyophilized peptide at -20 °C, protected from light and moisture. After reconstitution, keep at 2–8 °C for short-term work and aliquot for -20 °C storage to limit freeze-thaw cycles, confirming stability analytically before use.
References
For laboratory research use only. Not for human or veterinary use. Not for diagnostic or therapeutic use. These products have not been approved or evaluated by the U.S. Food and Drug Administration. No statement on this site has been evaluated by the FDA. These products are not intended to diagnose, treat, cure, mitigate, or prevent any disease, and are not intended for human or veterinary use. See our research-use terms and terms of service.